References
- Al-Shobaili HA, Al Robaee AA, Alzolibani AA, Rasheed Z. (2013). Immunological studies of reactive oxygen species damaged catalase in patients with systemic lupus erythematosus: Correlation with disease activity index. Immunol Investig, 42, 191–203
- Bartok B, Firestein GS. (2010). Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. Immunol Rev, 233, 233–55
- Bergtold A, Gavhane A, D'Agati V, et al. (2006). FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J Immunol, 177, 7287–95
- Beyaert R, Heyninck K, Van Huffel S. (2000). A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol, 60, 1143–51
- Buckley CD. (2011). Why does chronic inflammation persist: An unexpected role for fibroblasts. Immunol Lett, 138, 12–14
- Cho CS, Cho ML, Min SY, et al. (2000). CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. J Immunol, 164, 5055–61
- Coornaert B, Carpentier I, Beyaert R. (2009). A20: Central gatekeeper in inflammation and immunity. J Biol Chem, 284, 8217–21
- Franklyn K, Hoi A, Nikpour M, Morand EF. (2014). The need to define treatment goals for systemic lupus erythematosus. Nat Rev Rheumatol, 10, 567–71
- Garcia-Vicuna R, Gomez-Gaviro MV, Dominguez-Luis MJ, et al. (2004). CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheumat, 50, 3866–77
- Ghosh S, Hayden MS. (2008). New regulators of NF-kappaB in inflammation. Nat Rev Immunol, 8, 837–48
- Han JW, Zheng HF, Cui Y, et al. (2009). Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet, 41, 1234–7
- Hayden MS, West AP, Ghosh S. (2006). NF-kappaB and the immune response. Oncogene, 25, 6758–80
- Ivashkiv LB. (2011). Inflammatory signaling in macrophages: Transitions from acute to tolerant and alternative activation states. Eur J Immunol, 41, 2477–81
- Katsiari CG, Liossis SN, Sfikakis PP. (2010). The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: A reappraisal. Semin Arthritis Rheumat, 39, 491–503
- Li D, Wang L, Fan Y, et al. (2012). Down-regulation of A20 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Clin Immunol, 32, 1287–91
- Majumdar I, Paul J. (2014). The deubiquitinase A20 in immunopathology of autoimmune diseases. Autoimmunity, 47, 307–19
- Noss EH, Brenner MB. (2008). The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev, 223, 252–70
- Pfoh R, Lacdao IK, Saridakis V. (2015). Deubiquitinases and the new therapeutic opportunities offered to cancer. Endocr-Relat Cancer, 22, T35–54
- Shin MS, Kang Y, Lee N, et al. (2013). Self double-stranded (ds)DNA induces IL-1beta production from human monocytes by activating NLRP3 inflammasome in the presence of anti-dsDNA antibodies. J Immunol, 190, 1407–15
- Venegas-Pont M, Manigrasso MB, Grifoni SC, et al. (2010). Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension, 56, 643–9
- Vereecke L, Beyaert R, van Loo G. (2009). The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol, 30, 383–91
- Wang S, Wen F, Wiley GB, et al. (2013). An enhancer element harboring variants associated with systemic lupus erythematosus engages the TNFAIP3 promoter to influence A20 expression. PLoS Genet, 9, e1003750
- Zhu W, Yu J, Nie Y, et al. (2014). Disequilibrium of M1 and M2 macrophages correlates with the development of experimental inflammatory bowel diseases. Immunol Investig, 43, 638–52